U.S. flag

An official website of the United States government

GTR Home > Tests > Pharmacogenomic Testing


Sample Negative Report


Not provided

Sample Positive Report


Not provided

Variants Of Unknown Significance (VUS) Policy And Interpretation

What is the protocol for interpreting a variation as a VUS? Help
CPIC and DPWG guidelines are available on the PharmGKB website www.pharmgkb.org/view/dosing-guidelines.do
What is the laboratory's policy on reporting novel variations? Help
The current list of reported haplotypes are below. Unless otherwise indicated, the *1 allele denotes the absence of any variant and is designated as the wild type: CYP2D6*2 (LRG_303:g.7870C>T; 9200G>C), *3 (LRG_303:g.7569del), *4 (LRG_303:g.[5119C>T; 6866G>A; 9200G>C]), *5 (del(CYP2D6)), *6 (LRG_303:g.6727del), *7 (LRG_303:g.7955A>C), *8 (LRG_303:g.[6778G>T; 7870C>T; 9200G>C), *9 (LRG_303:g. 7635_7637del), *10 (LRG_303:g.[5119C>T; 9200G>C]), *11 (LRG_303:g.[ 9200G>C ;590G>C]), *12 (LRG_303:g.
Are family members with defined clinical status recruited to assess significance of VUS without charge?Help
Decline to answer, N/A
Will the lab re-contact the ordering physician if variant interpretation changes? Help


Is research allowed on the sample after clinical testing is complete?Help
Not provided

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.